Evaluation of BCGΔBCG1419c:ESAT6-PE25SS in immunocompetent and immunocompromised mouse models of TB (Old ID 27605)
Role
Principal Investigator
Description
Tuberculosis (TB) is a major public health concern that causes more than 1.5 million deaths each year. Vaccination is considered one of the most effective ways to eliminate TB. However, the only licensed TB vaccine, called BCG, provides limited protection against the disease in adults and can cause dangerous side effects in people with weaker immune systems. This project aims to investigate whether a new vaccine candidate can induce a stronger immune response and better protection against tuberculosis in mice with normal immune systems and is well-tolerated in mice with compromised immune systems, when compared with the original BCG vaccine.
Date
01 Jun 2022 - 31 May 2023
Project Type
GRANT
Keywords
Mycobacterium Tuberculosis;Vaccine Development;Immunology;Bcg;Infectious deseases
Funding Body
VALIDATE
Amount
98016
Project Team
Guangzu Zhao;Socorro Miranda-Hernandez;Andreas Kupz